Tuesday , October 24 2017

From the Editor

October, 2017

  • 24 October

    Oct. 24, 2017

    It is not unusual for many of us to begin to take things about diabetes for granted and forget to share some information with our patients. After showing many people how to use an insulin pen, medical professionals often will forget little things like taking the cap off of the ...

    Read More »

Latest Articles

October, 2017

  • 24 October

    Teaching Children to Manage Diabetes Has Its Limits

    SONY DSC

    Female, 25 years of age related a story to me she recalls from years back. Patient was diagnosed with type 1 diabetes at 5 years of age. Mother has had type 1 diabetes since childhood, so patient had learned a lot about living with type 1 diabetes since a young child. Patient is and has been a very independent person. Both her mother and father trusted her and for the most part worked with her pediatrician to manage her diabetes.

    Read More »
  • 24 October

    Osama Hamdy Part 4, Fasting with Diabetes

    OsamaHamdyAmazon

    In Part 4 of this Exclusive Interview, Dr. Osama Hamdy talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about how to safely fast to benefit weight loss and how to eat for maximum satiety.

    Read More »
  • 24 October

    Albuminuria: A Lot More Than Just a Little Protein in the Urine Part 10

    iStock_000016469615_Smalldiseased kidney

    In this week's Homerun Slides, a focus on empagliflozin, another therapeutic approach in the treatment of CKD in this albuminuria presentation by Dr. Claude Lardinois.

    Read More »
  • 24 October

    International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #96: Metabolomics: Applications in Type 2 Diabetes Mellitus and Insulin Resistance Part 2

    DeFronzoCover

    What is “metabolomics?” Metabolomics is an emerging field of analytical chemistry whose goal is to quantify all metabolites in a biologic sample, typically through application of multiple analytical platforms that enable determinations across a variety of metabolite classes. As with other omics-based technologies, this comprehensive coverage of metabolism has the benefit of allowing the observation of metabolic stressor effects not only at a single target, but also the ripple effect of the stressor, including compensatory responses, across the metabolic landscape.

    Read More »
  • 21 October

    Adding GLP-1 to Insulin

    Insulin injection pen

    Patients with type 2 diabetes not responding to basal insulin therapy alone may see glycemic improvement with a GLP-1 receptor agonist.

    Read More »

Test Your Knowledge

Lifestyle Modifications

Your 42-year-old, overweight patient was diagnosed with type 2 diabetes (A1C 7.7%) five months ago. You discussed the diagnosis with him, prescribed metformin, and provided lifestyle modification education resources. He missed his follow-up appointment, so you called him to schedule a return visit. At this appointment, he shares some of the positive lifestyle modifications he has made and that he has been taking his metformin consistently. He currently takes 2,000 mg metformin per day. At this visit, his A1C is 9.4%. All of the following are reasonable treatment options EXCEPT:

Correct

Correct Answer: A. Metformin + Lifestyle modifications

Educational Critique: According to ADA/EASD guidelines, once A1C=9%, glycemic targets are hard to achieve with monotherapy. If, after approximately a 3-month treatment period, monotherapy does not achieve or maintain target A1C, a second oral agent, a GLP-1 receptor agonist or a basal insulin should be added. Adding a second agent is associated with an additional A1C reduction of 1%. A, B, and C are all acceptable 2-drug combinations. Additional education, support and more frequent follow-up would be warranted.  Diabetes Care Jan. 2017

Incorrect

More Articles

October, 2017